U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck ’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older
KENILWORTH, N.J.--(BUSINESS WIRE) January 12, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Canada Health | Clinical Trials | Food and Drug Administration (FDA) | Meningitis Vaccine | Merck | Pharmaceuticals | Pneomococcal Vaccine | USA Health | Vaccines